Array BioPharma will restructure in an effort to extend its financial resources to focus on the development of key clinical programs: ARRY-520, a KSP inhibitor for multiple myeloma, ARRY-614, a p38 / Tie-2 inhibitor for myelodysplastic syndrome, and MEK162, a MEK inhibitor for cancer in co-development with Novartis. The restructuring will result in a reduction of staff by approximately 20%, or 70 employees. The cuts will be in discovery research and support positions. Array will retain a smalle...